<DOC>
	<DOCNO>NCT01591785</DOCNO>
	<brief_summary>Atopic dermatitis chronic disease characterize itch eczematous lesion . In adult , eczema commonly localizes hand foot . Several study implicate bacterial contamination , especially Staphylococcus aureus ( S. aureus ) , factor atopic dermatitis , infection bacteria correlate disease severity . No trial date investigate treat S. aureus infection adult hand hand/foot dermatitis . Using retapamulin ointment nose hand hands/feet , investigator expect significant clearance rate s. aureus infection . The investigator believe treat bacterial infection along treat condition topical corticosteroid significantly decrease severity hand/foot dermatitis study population .</brief_summary>
	<brief_title>Treatment Staphylococcus Aureus Colonization Hand Eczema</brief_title>
	<detailed_description>Primary Study Objectives : 1 . To evaluate efficacy retapamulin 1 % ointment clobetasol propionate 0.05 % foam versus vehicle ointment clobetasol propionate 0.05 % foam treatment regimen hand hand/foot atopic dermatitis . 2 . To evaluate incidence intranasal hand/foot S aureus carriage rate subject hand/foot atopic dermatitis via culture anterior nare severely grade target lesion hand/foot dermatitis . 3 . To evaluate incidence mupirocin-resistance methicillin-resistance S aureus isolate subject hand/foot atopic dermatitis via culture anterior nare severely grade target lesion hand/foot dermatitis . Primary secondary endpoint analyze appropriate statistical model qualify statistician . Any result pilot study treat exploratory hypothesis generating .</detailed_description>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<criteria>Male female subject least 18 year age clear diagnosis moderatetosevere hand hand/foot dermatitis . Subjects must general good health confirm medical history . Subjects must capable understand willing provide sign dated write voluntary informed consent protocol specific procedure perform . At Baseline Visit , Subjects must Physician 's Global Assessment ( PGA ) least 3 ( moderate severity ) . Subject must willing able participate study outpatient , make frequent visit study center treatment followup period period comply study requirement . If subject female childbearing potential must negative urine pregnancy test prior study treatment initiation must agree use approve method birth control study period ( barrier , oral , injection , intrauterine ) . NOTE : Postmenopausal ( amenorrhea least one year ) surgically sterile ( tubal ligation and/or hysterectomy ) females categorize nonchildbearing potential . NonEnglish speaking subject Females pregnant , breast feeding , attempt conceive . Subjects history know suspected intolerance excipients retapamulin 1 % ointment clobetasol propionate 0.05 % foam . Subjects use topical corticosteroid , topical antibiotic , topical immunosuppressant , topical therapy ( tar , calcineurin inhibitor ) , phototherapy ( PUVA , UVB ) within eight week Baseline Visit . Subjects use systemic corticosteroid , systemic antibiotic , systemic immunosuppressant therapy within eight week Baseline Visit . Subjects overt sign skin atrophy , telangiectasias , and/or stria target area ( ) . Subjects active skin malignancy . Subjects require use medication know alter course atopic dermatitis study period . Subjects currently participate , within previous 28 day , participate another study treatment atopic dermatitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Hand</keyword>
	<keyword>Foot</keyword>
	<keyword>Eczema</keyword>
	<keyword>Atopic Dermatitis</keyword>
</DOC>